Post-Marketing Surveillance Of Olmesartan Medoxomil In Combination With Hydrochlorothiazide

A Post Marketing Surveillance, Multicenter, Open-Label, Dose-Titrating, 4-Week Study Evaluating The Efficacy, Tolerability And Safety Of Olmesartan Medoxomil 20mg In Combination With 12.5mg Hydrochlorothiazide In Subjects With Stage 1 To Stage 2 Hypertension

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00796159

Enrollment

1723

Registered

2008-11-24

Start date

2007-07-31

Completion date

2008-12-31

Last updated

2009-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

Efficacy; Tolerability; Safety; Essential Hypertension

Brief summary

This is a Post-Marketing Surveillance study evaluating the Efficacy, Tolerability and Safety of Olmesartan medoxomil 20 mg in combination with 12.5 MG of hydrochlorothiazide in subjects with mild to moderate essential hypertension

Detailed description

Non Probability Sampling

Interventions

DRUGOlmesartan medoxomil

olmesartan medoxomil 20 mg and HCTZ 12.5 mg

Study design

Observational model

CASE_ONLY

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Male and Female patients 18 to 65 y/old * Patient previously taking low-dose medoxomil or any other ARB alone with uncontrolled BP * Patient with uncontrolled mild to moderate hypertension (SBP\>= 140 and \<=179 mmHg OR DBP of \>=90 and \<=109 mmHg)

Exclusion criteria

* Pregnant of Lactating women * History of secondary hypertension

Design outcomes

Primary

Measure	Time frame
Safety (Adverse Events)	4 weeks

Secondary

Measure	Time frame
Blood Pressure	4 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026